View in EDS HTML Full Text PDF Full Text

Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.

Saved in:
Bibliographic Details
Title: Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Authors: Watson, Zachary L.1 (AUTHOR), Yamamoto, Tomomi M.1 (AUTHOR), McMellen, Alexandra2 (AUTHOR), Kim, Hyunmin3 (AUTHOR), Hughes, Connor J.4 (AUTHOR), Wheeler, Lindsay J.5 (AUTHOR), Post, Miriam D.1,6 (AUTHOR), Behbakht, Kian1,5 (AUTHOR), Bitler, Benjamin G.1 (AUTHOR) benjamin.bitler@ucdenver.edu
Source: Clinical Epigenetics. 11/27/2019, Vol. 11 Issue 1, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:18687075
DOI:10.1186/s13148-019-0758-2